Estrogen, which is the main enemy of breast cancer patients, is curbed through SERM and AI. Master also shares these characteristics and is capable of preventing estrogen buildup in the body. As DHT derivative, it does not allow aromatization and displays strong anti-aromatase properties. For this reason, Masteron has been used in combination with other drugs to treat breast cancer patients. The role of Masteron then was to block the amount of estrogens in the body while other drugs, such as Tamoxifen-citrate were used to block the binding of estrogen at the breast receptors. Today, many other more powerful aromatase inhibitors have replaced this breast cancer treatment to achieve even greater success in the fight against breast cancer.
Trenbolone Hexahydrobenzylcarbonate represents the dominant large ester based Trenbolone compound on the market. It was first released by the France based Negma Laboratories in the late 1960’s under the trade name Parabolan. This represents the first and only Trenbolone hormone to ever exist in human grade form. Parabolan was prescribed for many years in cases of malnutrition, which will make a lot of sense as we dive into the compound. It was also prescribed to treat osteoporosis in some cases, as well as in the treatment of cachexia.